Rouyu Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rouyu Fang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Qiuning Sun
Department of Dermatology, Peking Union Medical College Hospital, Beijing, China
10 shared publications - Hanlin Zhang
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing
9 shared publications - Keyun Tang
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing 100730, China
5 shared publications Keyun Tang
Department of Dermatology Peking Union Medical College Hospital, No.1, Shuaifuyuan Beijing China
4 shared publications- Yuanzhuo Wang
Department of Dermatology Peking Union Medical College Hospital Beijing China
4 shared publications Yuchen Wang
Department of Dermatology Peking Union Medical College Hospital, No.1, Shuaifuyuan Beijing China
4 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (3) , e70799
Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis
Background: Mesotherapy, a widely utilized minimally invasive cosmetic procedure, carries potential risks of adverse reactions due to non‐standardized protocols and overuse. Delayed granulomatous reactions represent a chronic complication, imposing significant physical and psychological burdens on patients. Objective: This case series aims to evaluate the efficacy and safety of tofacitinib in managing non‐infectious granulomatous reactions following mesotherapy. Methods: This retrospective analysis included six patients diagnosed with non‐infectious granulomatous reactions post‐mesotherapy, treated at Peking Union Medical College Hospital between October 2021 and April 2025. All patients received oral tofacitinib. Clinical outcomes, treatment regimens, and safety profiles were assessed. Results: All six patients demonstrated significant improvement in skin lesion severity, with no treatment‐related adverse events observed during follow‐up. Conclusion: Oral tofacitinib exhibits promising clinical efficacy and a favorable safety profile for non‐infectious granulomatous reactions induced by mesotherapy, positioning it as a viable therapeutic option during the inflammatory phase.
- 19 March 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (3) , e70799
Open AccessClinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis
Background: Mesotherapy, a widely utilized minimally invasive cosmetic procedure, carries potential risks of adverse reactions due to non‐standardized protocols and overuse. Delayed granulomatous reactions represent a chronic complication, imposing significant physical and psychological burdens on patients. Objective: This case series aims to evaluate the efficacy and safety of tofacitinib in managing non‐infectious granulomatous reactions following mesotherapy. Methods: This retrospective analysis included six patients diagnosed with non‐infectious granulomatous reactions post‐mesotherapy, treated at Peking Union Medical College Hospital between October 2021 and April 2025. All patients received oral tofacitinib. Clinical outcomes, treatment regimens, and safety profiles were assessed. Results: All six patients demonstrated significant improvement in skin lesion severity, with no treatment‐related adverse events observed during follow‐up. Conclusion: Oral tofacitinib exhibits promising clinical efficacy and a favorable safety profile for non‐infectious granulomatous reactions induced by mesotherapy, positioning it as a viable therapeutic option during the inflammatory phase.
- 30 June 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (4) , 1695-1704
Topical calcineurin inhibitors as a double‐edged sword in rosacea: A systematic review
Background: Rosacea is a chronic inflammatory disease mainly with skin or ocular manifestations. Topical calcineurin inhibitors, pimecrolimus and tacrolimus, can be used to treat rosacea. However, they can also induce rosacea‐like eruptions.Aims: This study systematically reviewed the double‐edged sword effects of pimecrolimus and tacrolimus on rosacea.Methods: Four databases were retrieved to search for articles on the effects of pimecrolimus and tacrolimus on rosacea, including Cochrane Library, Embase, PubMed, and Web of Science. Only English articles were included in the systematic review. Relevant data were collected, and the levels of evidence were evaluated.Results: 28 articles published between 2001 and 2016 were included. 11 articles were about pimecrolimus as the treatment of rosacea, 4 articles were about the pimecrolimus‐induced rosacea, 9 articles were about tacrolimus as the treatment of rosacea, and 4 articles were about tacrolimus‐induced rosacea. Participants for each study ranged from 1 to 200. Several types of outcome measurements were used for these publications.Conclusions: Both pimecrolimus and tacrolimus might have double‐edged sword effects on rosacea. Pimecrolimus and tacrolimus could be effective for rosacea. However, both of them could also induce rosacea. Larger, randomized, controlled studies on pimecrolimus and tacrolimus as the treatment of rosacea and studies on the mechanisms of pimecrolimus and tacrolimus in treating or inducing rosacea are needed. This systematic review emphasized the double‐edged sword role of topical calcineurin inhibitors in rosacea, which may pave the way for future research.
- 30 June 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (4) , 1695-1704
Topical calcineurin inhibitors as a double‐edged sword in rosacea: A systematic review
Background: Rosacea is a chronic inflammatory disease mainly with skin or ocular manifestations. Topical calcineurin inhibitors, pimecrolimus and tacrolimus, can be used to treat rosacea. However, they can also induce rosacea‐like eruptions.Aims: This study systematically reviewed the double‐edged sword effects of pimecrolimus and tacrolimus on rosacea.Methods: Four databases were retrieved to search for articles on the effects of pimecrolimus and tacrolimus on rosacea, including Cochrane Library, Embase, PubMed, and Web of Science. Only English articles were included in the systematic review. Relevant data were collected, and the levels of evidence were evaluated.Results: 28 articles published between 2001 and 2016 were included. 11 articles were about pimecrolimus as the treatment of rosacea, 4 articles were about the pimecrolimus‐induced rosacea, 9 articles were about tacrolimus as the treatment of rosacea, and 4 articles were about tacrolimus‐induced rosacea. Participants for each study ranged from 1 to 200. Several types of outcome measurements were used for these publications.Conclusions: Both pimecrolimus and tacrolimus might have double‐edged sword effects on rosacea. Pimecrolimus and tacrolimus could be effective for rosacea. However, both of them could also induce rosacea. Larger, randomized, controlled studies on pimecrolimus and tacrolimus as the treatment of rosacea and studies on the mechanisms of pimecrolimus and tacrolimus in treating or inducing rosacea are needed. This systematic review emphasized the double‐edged sword role of topical calcineurin inhibitors in rosacea, which may pave the way for future research.
- 19 April 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (3) , 905-909
Murine models of rosacea: a review
Rosacea is a chronic inflammatory disease characterized by facial flushing, erythema, telangiectasia, papules, and pustules. Its pathogenesis has not been fully understood. In 2017, the global ROSacea COnsensus (ROSCO) panel updated the diagnosis, classification, and assessment of rosacea. Phenotype‐based treatments and long‐term managements have also been recommended. Murine models are a powerful tool in unveiling and dissecting the mechanisms of human diseases. Here, we summarized murine models of rosacea developed or used in previous research, including LL‐37 intradermal injection model, KLK‐5‐induced inflammation model, croton oil inflammation model, 12‐O‐Tetradecanoylphorbol‐13‐acetate inflammation model, arachidonic acid inflammation model, RTX‐induced vasodilation model, and UVB‐induced model. LL‐37 injection model has become the most intensively used model in rosacea research. Each model could show the pathophysiological and clinical features of rosacea to some extent. However, no model can show the full picture of the characteristics of rosacea. Improving existed murine models, developing new murine models, and applying them to pathogenesis and treatment research on rosacea are highly warranted in the future.
- 19 April 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (3) , 905-909
Murine models of rosacea: a review
Rosacea is a chronic inflammatory disease characterized by facial flushing, erythema, telangiectasia, papules, and pustules. Its pathogenesis has not been fully understood. In 2017, the global ROSacea COnsensus (ROSCO) panel updated the diagnosis, classification, and assessment of rosacea. Phenotype‐based treatments and long‐term managements have also been recommended. Murine models are a powerful tool in unveiling and dissecting the mechanisms of human diseases. Here, we summarized murine models of rosacea developed or used in previous research, including LL‐37 intradermal injection model, KLK‐5‐induced inflammation model, croton oil inflammation model, 12‐O‐Tetradecanoylphorbol‐13‐acetate inflammation model, arachidonic acid inflammation model, RTX‐induced vasodilation model, and UVB‐induced model. LL‐37 injection model has become the most intensively used model in rosacea research. Each model could show the pathophysiological and clinical features of rosacea to some extent. However, no model can show the full picture of the characteristics of rosacea. Improving existed murine models, developing new murine models, and applying them to pathogenesis and treatment research on rosacea are highly warranted in the future.
- Open Access
- 1 April 2021
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 14, 407-417
Use of Botulinum Toxin in Treating Rosacea: A Systematic Review
Background: Rosacea is a chronic skin disorder characterized by erythema, flushing, telangiectasia, papules and pustules, phymatous changes, and ocular involvement. The aim of this study was to examine all published research articles in which botulinum toxin was used to treat rosacea and to evaluate the efficacy and safety of this treatment. Methods: PubMed, Embase, Cochrane Library, and Web of Science database were used to identify articles eligible for systematic review on March 26, 2021. Prospective or retrospective studies which directly used botulinum toxin to treat rosacea were included and reviewed. Results: Nine studies were included in this systematic review. Two were randomized controlled trials, graded as Level 2 for the quality of evidence. The total number of participants was 130, and the number of participants in each study ranged from 1 to 25. The improvement was observed in all studies in signs and symptoms compared with baseline. Adverse events were transitory and self-limited. Conclusion: Botulinum toxin could have overall satisfying efficacy and safety in the treatment of rosacea, though limited by small sample size, imperfect study design, and short follow-up visits.
- 1 April 2021
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 14, 407-417
Open AccessUse of Botulinum Toxin in Treating Rosacea: A Systematic Review
Background: Rosacea is a chronic skin disorder characterized by erythema, flushing, telangiectasia, papules and pustules, phymatous changes, and ocular involvement. The aim of this study was to examine all published research articles in which botulinum toxin was used to treat rosacea and to evaluate the efficacy and safety of this treatment. Methods: PubMed, Embase, Cochrane Library, and Web of Science database were used to identify articles eligible for systematic review on March 26, 2021. Prospective or retrospective studies which directly used botulinum toxin to treat rosacea were included and reviewed. Results: Nine studies were included in this systematic review. Two were randomized controlled trials, graded as Level 2 for the quality of evidence. The total number of participants was 130, and the number of participants in each study ranged from 1 to 25. The improvement was observed in all studies in signs and symptoms compared with baseline. Adverse events were transitory and self-limited. Conclusion: Botulinum toxin could have overall satisfying efficacy and safety in the treatment of rosacea, though limited by small sample size, imperfect study design, and short follow-up visits.
- 2 February 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (5) , 1396-1402
Botulinum toxin in treating Hailey‐Hailey disease: A systematic review
Background: Hailey‐Hailey disease is a rare disorder characterized by recurrent painful blistering, erosions, maceration in the intertriginous regions. Botulinum toxin has been used in the treatment of Hailey‐Hailey disease.Aims: This study aimed to examine all published articles on botulinum toxin in the treatment of Hailey‐Hailey disease, and to evaluate its efficacy and safety.Methods: PubMed, Embase, Cochrane Library, and Web of Science were used to identify eligible articles on August 8, 2020. The searching strategy was “(Hailey Hailey or Hailey‐Hailey or pemphigus) and botulinum.”Results: Sixteen articles including 38 patients described the use of botulinum toxin in treating Hailey‐Hailey disease. Only one case had no response, while the other patients all had partial or complete remission. No side effects were reported. Nine articles including 10 patients mainly described other treatment options, and the patients were only treated with botulinum toxin previously. Their responses to botulinum toxin were limited: one was mild improvement, one was partial response, and the other eight failed.Conclusion: Botulinum toxin is not almighty, but a promising alternative option. We recommend botulinum toxin as an adjuvant or supplemental treatment modality for severe and recalcitrant Hailey‐Hailey disease. Larger studies are warranted to confirm its efficacy, safety, long‐term effects, and cost performance.
- 2 February 2021
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 20 (5) , 1396-1402
Botulinum toxin in treating Hailey‐Hailey disease: A systematic review
Background: Hailey‐Hailey disease is a rare disorder characterized by recurrent painful blistering, erosions, maceration in the intertriginous regions. Botulinum toxin has been used in the treatment of Hailey‐Hailey disease.Aims: This study aimed to examine all published articles on botulinum toxin in the treatment of Hailey‐Hailey disease, and to evaluate its efficacy and safety.Methods: PubMed, Embase, Cochrane Library, and Web of Science were used to identify eligible articles on August 8, 2020. The searching strategy was “(Hailey Hailey or Hailey‐Hailey or pemphigus) and botulinum.”Results: Sixteen articles including 38 patients described the use of botulinum toxin in treating Hailey‐Hailey disease. Only one case had no response, while the other patients all had partial or complete remission. No side effects were reported. Nine articles including 10 patients mainly described other treatment options, and the patients were only treated with botulinum toxin previously. Their responses to botulinum toxin were limited: one was mild improvement, one was partial response, and the other eight failed.Conclusion: Botulinum toxin is not almighty, but a promising alternative option. We recommend botulinum toxin as an adjuvant or supplemental treatment modality for severe and recalcitrant Hailey‐Hailey disease. Larger studies are warranted to confirm its efficacy, safety, long‐term effects, and cost performance.
- 27 October 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (12) , 3414-3415
Rosacea and its comorbidities: Should be emphasized but should not be overemphasized
- 27 October 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (12) , 3414-3415
Rosacea and its comorbidities: Should be emphasized but should not be overemphasized
- 5 August 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (12) , 3446-3447
Understanding and caring for lesbian, gay, bisexual, and transgender patients in dermatologic clinics: A dermatologist’s perspective from China
- 5 August 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (12) , 3446-3447
Understanding and caring for lesbian, gay, bisexual, and transgender patients in dermatologic clinics: A dermatologist’s perspective from China
- 3 August 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (10) , 2560-2565
Botulinum toxin as a double‐edged sword in alopecia: A systematic review
Background: Alopecia is a common disease influencing the quality of life of the patients. Botulinum toxin has been widely employed in cosmetic dermatology and was applied in some clinical trials to treat alopecia.Aims: Hence, We conducted a systematic review to examine the safety and efficacy of using botulinum toxin in treating alopecia.Methods: Cochrane Library, Embase, PubMed, and Web of Science databases were used to search for articles. A PICOS question was formed and the author, year of publication, number of participants, study design, product, dilution and dosing, outcome measurement, findings, side effects, and follow‐up were retrieved. The Oxford Centre for Evidence‐Based Medicine 2011 Levels of Evidence was used as a qualitative indicator to evaluate the levels of evidence.Results: Eleven articles published between 2005 and 2019 were included. 9 of which were about treatment effects and 2 were concerning adverse effects. The total number of the participants was 106, and the number for each article was ranged from 1 to 50. Varying type of outcome measurements was used for the publications. 8 articles were evaluated as Level 4 and 1 was evaluated as Level 5 during the 9 articles with treatment effects.Conclusions: The results showed that botulinum toxin may function as a double‐edged sword and have a low degree of efficacy and safety in treating alopecia. The study may be useful to remind the physicians of adverse effects in clinical practice and pave the way for further research. A larger, randomized, placebo‐controlled study is warranted.
- 3 August 2020
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 19 (10) , 2560-2565
Botulinum toxin as a double‐edged sword in alopecia: A systematic review
Background: Alopecia is a common disease influencing the quality of life of the patients. Botulinum toxin has been widely employed in cosmetic dermatology and was applied in some clinical trials to treat alopecia.Aims: Hence, We conducted a systematic review to examine the safety and efficacy of using botulinum toxin in treating alopecia.Methods: Cochrane Library, Embase, PubMed, and Web of Science databases were used to search for articles. A PICOS question was formed and the author, year of publication, number of participants, study design, product, dilution and dosing, outcome measurement, findings, side effects, and follow‐up were retrieved. The Oxford Centre for Evidence‐Based Medicine 2011 Levels of Evidence was used as a qualitative indicator to evaluate the levels of evidence.Results: Eleven articles published between 2005 and 2019 were included. 9 of which were about treatment effects and 2 were concerning adverse effects. The total number of the participants was 106, and the number for each article was ranged from 1 to 50. Varying type of outcome measurements was used for the publications. 8 articles were evaluated as Level 4 and 1 was evaluated as Level 5 during the 9 articles with treatment effects.Conclusions: The results showed that botulinum toxin may function as a double‐edged sword and have a low degree of efficacy and safety in treating alopecia. The study may be useful to remind the physicians of adverse effects in clinical practice and pave the way for further research. A larger, randomized, placebo‐controlled study is warranted.
- 2 July 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (4) , e13713
Contributions of dermatologists to COVID ‐19 research: A brief systematic review
Coronavirus Disease 2019 (COVID‐19) has been declared a pandemic. We conducted a systematic review to reveal the contribution of dermatologists in COVID‐19 research. 298 articles were included and classified into cutaneous manifestations of COVID‐19, operating experience against COVID‐19, mechanisms and treatment of COVID‐19, disinfection and personal protective equipment(PPE)‐related skin diseases and other topics. The value of these articles and their impact on clinical impact were discussed and we hope that dermatologists can have a better understanding of these areas from this study.
- 2 July 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (4) , e13713
Contributions of dermatologists to COVID ‐19 research: A brief systematic review
Coronavirus Disease 2019 (COVID‐19) has been declared a pandemic. We conducted a systematic review to reveal the contribution of dermatologists in COVID‐19 research. 298 articles were included and classified into cutaneous manifestations of COVID‐19, operating experience against COVID‐19, mechanisms and treatment of COVID‐19, disinfection and personal protective equipment(PPE)‐related skin diseases and other topics. The value of these articles and their impact on clinical impact were discussed and we hope that dermatologists can have a better understanding of these areas from this study.
- 22 May 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (4) , e13528
Cutaneous manifestations of the Coronavirus Disease 2019 ( COVID ‐19): A brief review
COVID‐19, first appeared in December 2019 in Wuhan, China, has been spreading quickly throughout the world. We reviewed the evidence on cutaneous manifestations of COVID‐19 based on PubMed database. The searching strategy was (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. After independent review by two authors, 14 studies with 228 confirmed cases were included in the analysis. A total of 60 patients developed skin rashes, and the age ranged from 8 to 84. Exanthematous eruptions potentially related to COVID‐19 infection were highly variable and heterogeneous. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox‐like or varicelliform). Petechiae rash, livedo reticularis, and reactivation of oral HSV‐1 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis‐like) skin lesions caused concern among dermatologists. Exanthems were widely distributed and were primarily located on the trunk. Associated symptoms, latency time, treatment, and prognosis were also carefully summarized. This study reviewed the recently published COVID‐19 studies with skin manifestations, which may pave the way for further research.
- 22 May 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (4) , e13528
Cutaneous manifestations of the Coronavirus Disease 2019 ( COVID ‐19): A brief review
COVID‐19, first appeared in December 2019 in Wuhan, China, has been spreading quickly throughout the world. We reviewed the evidence on cutaneous manifestations of COVID‐19 based on PubMed database. The searching strategy was (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. After independent review by two authors, 14 studies with 228 confirmed cases were included in the analysis. A total of 60 patients developed skin rashes, and the age ranged from 8 to 84. Exanthematous eruptions potentially related to COVID‐19 infection were highly variable and heterogeneous. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox‐like or varicelliform). Petechiae rash, livedo reticularis, and reactivation of oral HSV‐1 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis‐like) skin lesions caused concern among dermatologists. Exanthems were widely distributed and were primarily located on the trunk. Associated symptoms, latency time, treatment, and prognosis were also carefully summarized. This study reviewed the recently published COVID‐19 studies with skin manifestations, which may pave the way for further research.